This HTML5 document contains 193 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1182/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33387514
rdf:type
wikibase:Item
schema:description
2009年论文 2009年論文 mokslinis straipsnis 2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած научная статья επιστημονικό άρθρο مقالة علمية scienca artikolo 2009年论文 مقالهٔ علمی 2009年論文 vetenskaplig artikel wissenschaftlicher Artikel artikull shkencor vedecký článok наукова стаття, опублікована в грудні 2009 artículo científico publicado en 2009 articolo scientifico artigo científico (publicado na 2009) article científic 2009年論文 bài báo khoa học 2009 nî lūn-bûn tieteellinen artikkeli vědecký článek article scientifique (publié 2009) 2009年论文 2009年论文 2009年の論文 teaduslik artikkel мақолаи илмӣ videnskabelig artikel (udgivet 2009) artículu científicu espublizáu en 2009 vitenskapelig artikkel articol științific article scientific scientific article artigo científico (publicado na 2009) naučni članak 2009年論文 2009년 논문 научни чланак научна статия artykuł naukowy artikulong pang-agham научни чланак vitskapeleg artikkel 2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված 2009年论文 2009年論文 ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ სამეცნიერო სტატია tudományos cikk سائنسی مضمون 2009年论文 wetenschappelijk artikel บทความทางวิทยาศาสตร์ מאמר מדעי мақолаи илмӣ artigo científico bilimsel makale
p:P577
wds:Q33387514-6A243CD9-4DB9-4180-8FAF-297B4392F89E
wdt:P577
2009-12-11T00:00:00Z
p:P407
wds:Q33387514-63BCC11D-1FE9-4775-BFFC-8FF012F69AA9
wdt:P407
wd:Q1860
p:P2860
wds:Q33387514-A2618F5E-836C-4691-A8B1-B6F2DF668EDA wds:Q33387514-A415B7B0-F7A6-45B6-BE2D-3F3DB7597495 wds:Q33387514-A864F1AE-42EA-42C1-AAE3-11B8949A4D51 wds:Q33387514-F2E09E0C-DDD3-4A24-B88C-076720902643 wds:Q33387514-E2C507E2-E402-408F-823C-0A5FFC77C177 wds:Q33387514-EDA1BA29-DFAA-4855-9077-AFBCE15AFC7E wds:Q33387514-EE039530-9CD5-4914-B017-F681165D2B2D wds:Q33387514-44317A6E-93A6-4D09-9FAE-B7C819857A70 wds:Q33387514-4575CF3C-2845-4BC1-940A-9111FB7FAB3C wds:Q33387514-3D778AF0-E2CC-4BB0-A731-3C17B2EE7DC6 wds:Q33387514-34EBF7B1-E2D5-434C-817C-2D79B9550C0E wds:Q33387514-39332809-D4C0-41B5-9201-0F668BD7A2D7 wds:Q33387514-3B131D87-6A63-41EF-BF40-E6252B513B7F wds:Q33387514-2FF8F5B0-ECCF-4D85-870C-6663E64954BC wds:Q33387514-7BFDD4CB-628D-4A86-B4E3-FC55C9C5A2FF wds:Q33387514-92B98F47-136A-4937-8DB8-16EF210E945A wds:Q33387514-93BC2ED3-E71D-4CE0-B511-5CEC7AB40D52 wds:Q33387514-98152644-F295-4BB4-BC16-CA3AFB44BCB6 wds:Q33387514-6D669624-B42C-48CD-8828-700AD4BC30A0 wds:Q33387514-70B22612-1963-42AC-A404-47AF9C30D866 wds:Q33387514-76A18158-12BA-425A-B51C-A001F7E6E958 wds:Q33387514-7AFEC7A4-51A4-44D5-9BFE-3F722550B1A3 wds:Q33387514-608DFA59-74B2-44C5-A03C-4E96E4280EBA wds:Q33387514-480C50EB-A06A-4663-99B4-A81087A70D3E wds:Q33387514-5623868A-E2D3-43F6-9981-1E9477B5A5E5 wds:Q33387514-5BFDE445-ED7A-44C2-84C7-503F67A81300 wds:Q33387514-0B344652-3682-4C66-AA4C-623E7ABB9032 wds:Q33387514-15A2B920-B3CE-46A9-8819-AED11AEB5D0F wds:Q33387514-174E1125-1FB3-4756-AC9B-A590837B3700 wds:Q33387514-2761A54F-7A95-421E-A30E-D430DF2951E3 wds:Q33387514-C909492D-8D56-4174-B3C5-BEBC44708B47 wds:Q33387514-CB23AAA4-E6F8-4C69-8EF0-2261593AC9D8 wds:Q33387514-D13FA1B0-29EB-45AE-813A-AC3645940EF9 wds:Q33387514-BED643CB-A2C9-4D69-8F6C-4B799A2E49E4 wds:Q33387514-C102884D-3A0B-4FC5-A52F-6355E1CB0BC4 wds:Q33387514-C645E0C9-29EF-41B0-9CF7-15182EC5D86C wds:Q33387514-A23D25BA-4F76-4555-B18D-85EF5761A7B8
wdt:P2860
wd:Q29619292 wd:Q80070172 wd:Q36468734 wd:Q28270987 wd:Q37255024 wd:Q53661302 wd:Q40650130 wd:Q37250023 wd:Q79802927 wd:Q80969122 wd:Q81442307 wd:Q29614601 wd:Q34180677 wd:Q35873624 wd:Q24657681 wd:Q34626628 wd:Q29618851 wd:Q27824808 wd:Q29547776 wd:Q33371084 wd:Q33370690 wd:Q53608822 wd:Q82045907 wd:Q28217482 wd:Q29618853 wd:Q46412217 wd:Q29614337 wd:Q36788138 wd:Q36779588 wd:Q35849674 wd:Q51023659 wd:Q29619657 wd:Q36509770 wd:Q36509804 wd:Q36609417 wd:Q28241887 wd:Q80866784
p:P2093
wds:Q33387514-29C33DF7-A1AA-4075-A474-B4DE34889512 wds:Q33387514-2C37A883-F68A-4AB0-8908-F212638EF160 wds:Q33387514-DA6027AC-CFD0-4CD1-85BE-914EB207CCE8 wds:Q33387514-B0209EAB-9556-476C-AA87-52F15302D461
wdt:P2093
Fabio P S Santos Nitin Jain Deborah A Thomas Debra Kennedy
rdfs:label
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
skos:prefLabel
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
schema:name
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
p:P50
wds:Q33387514-E90518EC-11C5-406E-A7FD-7755C5EF21EA wds:Q33387514-EF897D53-814A-4BC5-AB2E-A145F54D564F wds:Q33387514-AC5949E9-9329-4513-8159-6B627BC76337 wds:Q33387514-AD84DFC0-3B17-4FCB-91A6-DEDFDDD4BE29 wds:Q33387514-B27B4A61-F29F-4FCD-BC11-14EBC4E158B9 wds:Q33387514-5D44447B-2D23-4D8E-8427-0E618D7FCCCC
wdt:P50
wd:Q66385413 wd:Q64026418 wd:Q60394812 wd:Q91467065 wd:Q64026337 wd:Q60320900
p:P1476
wds:Q33387514-4113D987-8A59-4B1A-AE63-D1D6197065B2
wdt:P1476
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
p:P304
wds:Q33387514-388802E0-5EA3-499D-8706-22C8E8FE252D
wdt:P304
1131-1136
p:P31
wds:Q33387514-4A0ED853-6C4F-424D-BA71-B798AB800E8F
wdt:P31
wd:Q13442814
p:P921
wds:Q33387514-3C85AEA2-835B-4173-83D3-36F9302EA209
wdt:P921
wd:Q1752571
p:P698
wds:Q33387514-42C081C2-B809-4738-AA27-43889A61E240
wdtn:P698
n12:20008298
wdt:P698
20008298
p:P1433
wds:Q33387514-046CA0E9-35C7-4417-8FE5-DC8AEA9CFA1C
wdt:P1433
wd:Q885070
p:P433
wds:Q33387514-307B238E-F89F-41E6-AC33-9838BC326244
p:P478
wds:Q33387514-F8D6D439-3D6C-4789-8FB6-7C3B1F08F008
wdt:P433
6
wdt:P478
115
p:P356
wds:Q33387514-4212AAE5-0B94-4110-A309-E4E79D7AC212
wdtn:P356
n8:BLOOD-2009-10-246363
wdt:P356
10.1182/BLOOD-2009-10-246363
p:P5875
wds:Q33387514-C4685014-3183-4F26-801F-564D4509E33F
wdt:P5875
40686034
p:P932
wds:Q33387514-465393D4-FBAF-43BB-A7AD-3D6001B1B839
wdt:P932
4081385